Candonilimab

DRUG4 trials

Sponsors

Shi Ming, Second Affiliated Hospital, School of Medicine, Zhejiang University, West China Hospital

Conditions

Cholangiocarcinoma Non-resectableHepatocellular CarcinomaSoft Tissue Sarcoma

Phase 2

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Shi MingHepatocellular Carcinoma

Start: 2023-02-27End: 2024-07-01Target: 30Updated: 2023-03-08

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

WithdrawnNCT05886257

Shi MingHepatocellular Carcinoma

Start: 2022-12-07End: 2023-03-31Updated: 2023-06-02

Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment

RecruitingNCT05926700

Second Affiliated Hospital, School of Medicine, Zhejiang UniversitySoft Tissue Sarcoma

Start: 2024-02-28End: 2027-03-01Target: 27Updated: 2026-04-08

Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer

RecruitingNCT05978609

West China HospitalCholangiocarcinoma Non-resectable

Start: 2023-07-01End: 2026-07-01Target: 65Updated: 2023-08-07

Related Papers

Cadonilimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (BicureX): A phase II, single-arm clinical trial.

Journal of Clinical Oncology2025-05-28

Cadonilimab in combined with gemcitabine and cisplatin in advanced biliary tract cancer (BicureX): A phase II, single-arm clinical trial.

Journal of Clinical Oncology2024-06-011 citations